CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab
Crossref DOI link: https://doi.org/10.1186/s12967-015-0456-6
Published Online: 2015-04-01
Published Print: 2015-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Niehr, Franziska
Weichert, Wilko
Stenzinger, Albrecht
Budach, Volker
Tinhofer, Ingeborg
License valid from 2015-04-01
Article History
Received: 5 November 2014
Accepted: 10 March 2015
First Online: 1 April 2015